Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONMED CorpCNMD · Entity 4691 | VP GM International | March 03, 2025 | May 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONMED Corp
Report date March 03, 2025 · Filed May 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-03-03 | Direct | 17,144 |
Reported balance
After 2025-03-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-03 · Grant · Acquired 17,144 · Balance 17,144 F1: Represents the settlement of vested restricted stock units (RSUs) with the delivery of shares of common stock, subject to withholding for taxes. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2018 Long-Term Incentive Plan and generally vest in a four year period with zero (0) shares vesting in 2026; 8,572 shares vesting on 3/3/27; 6,429 shares vesting on 3/3/28 and 2,143 vesting on 3/3/29. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the settlement of vested restricted stock units (RSUs) with the delivery of shares of common stock, subject to withholding for taxes. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2018 Long-Term Incentive Plan and generally vest in a four year period with zero (0) shares vesting in 2026; 8,572 shares vesting on 3/3/27; 6,429 shares vesting on 3/3/28 and 2,143 vesting on 3/3/29.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed May 15, 2025 13:59 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 17,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-014389 · form4.xml · derivative · entry 1 Epinette Stephan · CIK 0001507941 · VP GM International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,144 Underlying: Common Stock · 17,144 shares Expires 2035-03-03 F1 · derivative.exercise_date: Represents the settlement of vested restricted stock units (RSUs) with the delivery of shares of common stock, subject to withholding for taxes. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2018 Long-Term Incentive Plan and generally vest in a four year period with zero (0) shares vesting in 2026; 8,572 shares vesting on 3/3/27; 6,429 shares vesting on 3/3/28 and 2,143 vesting on 3/3/29. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.